Icon

Dymista - (0.125mg/Spray; 0.05mg/Spray, Spary, Metered, Nasal)

Azelastine Hydrochloride and Fluticasone Propionate Mylan
0.125mg/Spray; 0.05mg/Spray, Spary, Metered, Nasal
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
Less Than 5
Less Than 5
Indicated for the relief of symptoms of seasonal allergic rhinitis in patients 6 years of age and older who require treatment with both azelastine hydrochloride and fluticasone propionate for symptomatic relief.
Yes
****** ** *** ***** ** **** **** ** **** ******* '*** *** **, ****, '*** *** **, ****, '*** *** **, **** *** *** ************ *********. **** *** ****** ** ** ****** ****, ********** *** ******* **** ****** ***** *** ***** ** ********** *** *** ****. ***** **** *** ******* ***** **** ** **** *** **** ******* *** **** ************ *********. ***** **** *** ***** ******* **** ******, **** *** ******* ***** *** ***** ** ********** *** ******* . *****, ******** *** *** ********** ****** *, *-*, **-**, **, *** **-** ** ******* (*** **, ****)-** ******* ******* *** ** ****. ******* ****** ** *******.
Dymista Patent 1 Patent 2 Patent 3 Patent 4
****** ******* ******* ******* *******
**** ******* ******* ******* *******
******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ *** **** *, **** ******* ******** ******** ** * *** ****
**** ** \ ** ***** *, **** ******* ********* ******** ***** *** ****
******* ** \ ** ***** *, **** ******* ******** ******** ** * *** ****
  1. *** *, **** : **** ****** ***** * **** ******* ******, ** ****** ***** * **** ** **** ******* '*** *** **, ****, '*** *** **, ****, '*** *** **, ****
  2. *** *, **** : **** ****** ***** * **** ******* ****, ** **** ***** * **** ** **** ******* '*** *** **, ****, '*** *** **, ****, '*** *** **, ****
  3. *** *, **** : **** ***** * **** ******* *******, ** ******* **** ****** ***** * **** ******* ******, ** ****** ***** * **** ** **** ******* '*** *** **, ****, '*** *** **, ****, '*** *** **, ****.
  4. *** **, **** : **** ******* **** ****** , ***** *** ***** ** ********** *** *** *****.
  5. *** **, **** : ******* ********* ********** **** **** *** ***** **** ******* ***** *****. *** ***** *** ********** ** ********** *** *** *****.
  6. *** **, **** : **** ******* **** ****, ***** *** ***** ** ********** *** *** *****.
  7. *** **, **** : ******** *** *** ********** ****** *, *-*, **-**, **, *** **-** ** ******* (*** **, ****)-** ******* ******* *** ** ****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.